Dapagliflozin Effect on Erythropoiesis and Physical Fitness

Sponsor
University Hospital Tuebingen
Study ID
NCT03423355
Phase
PHASE4
Status
Withdrawn

Conditions

  • Type 2 Diabetes Mellitus (T2DM)

Eligibility Criteria

Sex
ALL
Age
40 Years - 70 Years
Healthy Volunteers
Not accepted

Interventions

Study Details

Dapagliflozin effect on erythropoiesis and physical fitness in patients with type 2 diabetes - a randomized, partly double-blinded, controlled, three armed, parallel group, exploratory study

Key Dates

Start date
Sep 30, 2021
Status verified
Jul 2021
Primary completion
Mar 31, 2023
Completion
Dec 31, 2023

Study Design

Enrollment
0 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Active Comparator: Dapagliflozin (Forxiga®)
    Treatment with the SGLT2 inhibitor dapagliflozin 10 mg once daily for 28 days.
  • Placebo Comparator: Placebo matching Dapagliflozin
    Treatment with the Dapagliflozin matching placebo once daily for 28 days.
  • Other: Hydrochlorothiazide
    Treatment with the Hydrochlorothiazide 25 mg once daily for 28 days

Primary Outcome Measure

Change in blood EPO levels [ Time Frame: 2 weeks of treatment ]

Related Studies